These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27061776)

  • 21. A 600 mg of fixed-dose linezolid in renally impaired patients versus 15 mg/kg intermittent dose-optimized vancomycin in renally non-impaired patients: A single centre retrospective analysis for adult patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus.
    Wang M; Liu X; Tian Z
    Trop Med Int Health; 2023 Apr; 28(4):315-323. PubMed ID: 36852899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Lyles A
    Clin Ther; 2007 Feb; 29(2):384. PubMed ID: 17472833
    [No Abstract]   [Full Text] [Related]  

  • 23. Linezolid versus vancomycin cost in the treatment of staphylococcal pneumonia.
    Huon JF; Boutoille D; Caillon J; Orain J; Crochette N; Potel G; Abgueguen P; Moal F; Navas D
    Med Mal Infect; 2020 May; 50(3):252-256. PubMed ID: 31387813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.
    Alaniz C; Pogue JM
    Ann Pharmacother; 2012 Oct; 46(10):1432-5. PubMed ID: 22947593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daily practice and prognostic factors for pneumonia caused by methicillin-resistant Staphylococcus aureus in Japan: A multicenter prospective observational cohort study.
    Miyazaki T; Yanagihara K; Kakeya H; Izumikawa K; Mukae H; Shindo Y; Yamamoto Y; Tateda K; Tomono K; Ishida T; Hasegawa Y; Niki Y; Watanabe A; Soma K; Kohno S
    J Infect Chemother; 2020 Feb; 26(2):242-251. PubMed ID: 31575499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost of nosocomial pneumonia: the example of vancomycin versus linezolid-shorter stay or fewer complications?
    Rello J; Bin C
    Int J Infect Dis; 2016 Oct; 51():1-3. PubMed ID: 27524405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.
    Walkey AJ; O'Donnell MR; Wiener RS
    Chest; 2011 May; 139(5):1148-1155. PubMed ID: 20864609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.
    Wang Y; Zou Y; Xie J; Wang T; Zheng X; He H; Dong W; Xing J; Dong Y
    Eur J Clin Pharmacol; 2015 Jan; 71(1):107-15. PubMed ID: 25355172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.
    Mendes RE; Deshpande LM; Smyth DS; Shopsin B; Farrell DJ; Jones RN
    J Clin Microbiol; 2012 Nov; 50(11):3694-702. PubMed ID: 22972817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of clinical success among a national Veterans Affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia.
    Caffrey AR; Morrill HJ; Puzniak LA; LaPlante KL
    Clin Ther; 2014 Apr; 36(4):552-9. PubMed ID: 24631473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH
    Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstem R
    Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
    Maclayton DO; Hall RG
    Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
    Patel DA; Michel A; Stephens J; Weber B; Petrik C; Charbonneau C
    Infect Drug Resist; 2014; 7():273-80. PubMed ID: 25368526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Testing Reduces the Duration of MRSA-Targeted Therapy in Patients with Suspected MRSA Pneumonia.
    Baby N; Faust AC; Smith T; Sheperd LA; Knoll L; Goodman EL
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis.
    Liu P; Capitano B; Stein A; El-Solh AA
    BMC Nephrol; 2017 May; 18(1):168. PubMed ID: 28532398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia.
    Caffrey AR; Morrill HJ; Puzniak LA; Laplante KL
    Pharmacotherapy; 2014 May; 34(5):473-80. PubMed ID: 24420846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
    Bounthavong M; Hsu DI
    Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials.
    Jiang H; Tang RN; Wang J
    Eur J Clin Microbiol Infect Dis; 2013 Sep; 32(9):1121-8. PubMed ID: 23568605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.